EXACT THERAPEUTICS OSLO ,27 September 2023 :EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, is delighted to announce that Caspar Foghsgaard is joining the company as Senior Vice President Commercial and Business Development, effective1 November 2023 . "We are thrilled to welcome Caspar to our leadership team as our Senior Vice President of Commercial and Business Development. Caspar's extensive experience and dynamic approach will be instrumental in driving the future growth of EXACT-Tx. With the recent announcement of the positive initial clinical results from our ACTIVATE trial, we are entering an exciting phase, during which we will shape the future of the Company", says Per Walday, CEO of EXACT-Tx. Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his latest role was as Sr. Director Special Projects and part of the extended leadership team. He joined Nykode in 2018 and have been closely involved in Nykode's transformation from a small biotech to a leading company atOslo Stock Exchange . Prior to his role as Sr. Director Special Projects, he was heading Nykode's business development activities as Director Business Development. Other previous employers include Arcus where he was responsible for business development in the spirits division and part of the divisional management, andElopak as Program Director Strategy. In addition, he has held various business development and strategy positions including withNovozymes inDenmark ,U.S. andU.K. For more information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology, however the ACT® platform has potential across therapeutic areas (CNS, immunotherapy) and product classes. Forward looking statements: This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.
Click here for more information
© Oslo Bors ASA, source
